Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Regulus

Regulus

Sep 09, 2015

UCSD Researchers Win Grant to Develop Extracellular RNA Biomarker Panel for Glioma

Premium

The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics.

Feb 19, 2015

Regulus Plans for New Clinical Trials, Third Drug Candidate in '15

Premium

The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year.

Feb 09, 2015

New Data Shows Higher Dose of Regulus HCV Drug Offers Better Viral Load Reductions

Premium

The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.

Feb 02, 2015

Regulus Hits Milestone in Biogen Idec microRNA Biomarker Deal

Regulus said it was able to develop its miRNA extraction and profiling technology to meet the quality specifications set out by its partner.

Dec 03, 2014

Alnylam Publishes Paper on Development of GalNAc Conjugate Delivery Technology

Premium

The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.

Nov 24, 2014

Data Point to Regulus Alport Drug Use in Late-stage Disease, Other Kidney Diseases

Premium

The data show that RG-012 can enhance the effect of Sanofi's kidney protectant ramipril and suggest the microRNA drug might have use in other chronic kidney diseases.

Nov 06, 2014

Wall Street in October Proves Tumultuous for Four RNAi/microRNA Shops

Premium

NEW YORK (GenomeWeb) — October was a turbulent month on Wall Street for several key RNAi/microRNA players, with two companies — Regulus Therapeutics and Alnylam Pharmaceuticals — seeing major gains on encouraging clinical data and two others — Arrowhead Research and Tekmira Pharmaceuticals — taki

Nov 06, 2014

Regulus Weighs Dual Development Track for HCV Drug

Premium

NEW YORK (GenomeWeb) — Buoyed by positive Phase I data on its microRNA-targeting hepatitis C drug RG-101, Regulus Therapeutics is aiming to begin Phase II testing of the dr

Nov 06, 2014

Regulus Closes $103.5M Stock Offering

Premium

NEW YORK (GenomeWeb) — Regulus Therapeutics announced this week that it has closed its previously announced public stock offering, raising $103.5 million through the transaction.

Oct 30, 2014

Regulus to Raise $90M in Stock Offering

Premium

NEW YORK (GenomeWeb) — Regulus Therapeutics this week announced that it had priced its previously announced public offering of roughly 5.3 million shares of its common stock at $17 apiece, valuing the transaction at about $90 million.

Pages

The Scan

This Time, Novavax

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Shortened Visas for Some Students

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

New York's Own Review

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Science Papers Examine Y Chromosomes of Archaic Humans, Schistosomiasis Therapeutic Targets

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.